Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEXABRIX vs ISOVUE-M 200
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar),CT cisternography,Ventriculography
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Not metabolized; excreted unchanged by the kidneys. Undergoes passive resorption from cerebrospinal fluid into plasma.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Negligible (<5%); no specific binding proteins
Negligible, <2% bound to plasma proteins.
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Approximately 0.3–0.4 L/kg, consistent with distribution into extracellular fluid space.
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
Not applicable; administered intravenously or intra-arterially, with 100% bioavailability by these routes.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
e GFR ≥30 m L/min: No adjustment. e GFR <30 m L/min: Contraindicated due to risk of nephrogenic systemic fibrosis (NSF) with gadolinium-based agents; however, for iopamidol-based Isovue-M 200, renal impairment requires dose reduction and careful monitoring. In severe renal impairment (e GFR <30 m L/min), use lowest effective dose and ensure adequate hydration; consider alternative imaging.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
No specific Child-Pugh based adjustments recommended; use with caution in severe hepatic impairment due to potential for contrast-induced nephropathy and systemic effects.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
Intrathecal: 0.2-0.4 m L/kg (up to 12 m L total) for myelography. Intravenous: 1.5-2.5 m L/kg (max 200 m L) for CT or angiography, adjusted per procedure.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
Use with caution due to increased prevalence of renal impairment, cardiovascular disease, and dehydration. Assess renal function before use; ensure adequate hydration; consider lower doses and longer intervals between procedures.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
Risk of serious adverse reactions including anaphylaxis, seizures, and neurological complications when administered intrathecally. Use only by physicians trained in myelography and familiar with the procedure. Resuscitative equipment and trained personnel must be immediately available.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
Risk of anaphylactoid reactions, especially in patients with history of allergy or bronchial asthma,Seizures may occur, particularly in patients with epilepsy or when concurrent medications lower seizure threshold,Renal impairment delays elimination and increases risk of adverse effects,Adequate hydration before and after procedure is essential,Neurotoxicity: avoid hemorrhage or infection at puncture site, do not use in patients with increased intracranial pressure
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
Known hypersensitivity to iopamidol or any component of the formulation,Concurrent intrathecal administration of corticosteroids or other contrast agents,Blood in CSF (hemorrhagic puncture) due to increased risk of neurotoxicity,History of seizures or epilepsy (relative contraindication depending on benefit-risk),Severe renal impairment (relative, may be used after dialysis if necessary)
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
No specific food interactions. Maintain adequate hydration before and after contrast administration. Avoid alcohol consumption for 24 hours post-procedure as it may exacerbate CNS side effects.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when administered to a pregnant woman. However, iodinated contrast agents cross the placenta and accumulate in the fetal thyroid, potentially causing hypothyroidism. Use during pregnancy should be limited to situations where the diagnostic benefit clearly outweighs the risk. First trimester exposure is not advised due to organogenesis. Second and third trimester use may be considered with caution, but neonatal thyroid function should be assessed after birth.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
Iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma ratio (M/P) is approximately 0.01. After IV administration, the amount ingested by a nursing infant is minimal (<0.1% of the maternal dose). Because of the low bioavailability of oral iodinated contrast agents, adverse effects in the infant are unlikely. The American College of Radiology considers it safe to continue breastfeeding after use of iodinated contrast agents. However, some guidelines suggest discarding breast milk for 12-24 hours after administration if desired.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
No specific dose adjustment is required for iopamidol (ISOVUE-M 200) during pregnancy. However, the lowest effective dose necessary for diagnostic imaging should be used. The physiological changes of pregnancy (increased plasma volume, renal blood flow and GFR) may alter the pharmacokinetics of iopamidol, potentially leading to faster clearance. Nonetheless, no dose adjustment is recommended as contrast dosing is weight-based and the agent is used as a single dose for imaging.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
ISOVUE-M 200 (iopamidol) is a nonionic, low-osmolar iodinated contrast medium used for intrathecal administration in myelography. Pre-hydrate patients to reduce risk of contrast-induced nephropathy. Have resuscitation equipment available due to risk of anaphylactoid reactions. Avoid in patients with known hypersensitivity to iodine-containing compounds. Monitor for delayed adverse effects such as headache, nausea, and meningeal irritation.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
Inform your healthcare provider if you have any allergies, especially to iodine or contrast agents.,Tell your doctor if you have kidney problems, diabetes, or are taking certain medications like metformin.,Drink plenty of fluids before and after the procedure to help flush the contrast from your body.,You may experience headache, nausea, or back pain after the injection; report severe or persistent symptoms.,Avoid driving or operating machinery for at least 24 hours after the procedure due to possible dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or suspect you may be pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEXABRIX vs ISOVUE-M 200, answered by our medical review team.
HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. ISOVUE-M 200 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEXABRIX and ISOVUE-M 200 depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. The standard adult dose of ISOVUE-M 200 is: Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HEXABRIX and ISOVUE-M 200 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. ISOVUE-M 200 is classified as Category C. Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.